BOSTON, Sept. 27, 2026 /PRNewswire/ — Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world’s first pediatric treatments using an upright positioning and imaging platform, Marie®, the company has confirmed it has developed a dedicated pediatric program bringing together education, distraction and gamification.

First pediatric treatments

In June 2026, Stanford Medicine delivered the first treatments using the Mevion S250-FIT Proton Therapy System™, which integrates Leo Cancer Care’s Marie® upright positioning and imaging solution and utilizes RaySearch Laboratories’ RayStation® planning system.

These early treatments have shown not only that upright pediatric proton therapy is feasible, but that it can be applied across a wide pediatric age range, and that anesthesia remains available where it is the right clinical choice.

A more natural position for children

The company set out to develop a platform that would simplify the delivery of, and access to, radiation therapy by rethinking the conventional approach. Instead of moving the radiation beam around a patient lying down, their solution inverts this: The beam stays fixed while the patient, seated or semi-standing, is rotated to treatment positions in front of it.

An upright position also encourages more active participation. When children can sit or stand, it is easier for them to play an active role in their treatment, which may help reduce fear and foster a sense of control.

Unlocking imaginations to design a new experience

The foundation of the new experience is underpinned by the premise that a chair can become, in a child’s imagination, the seat of a rocket ship blasting off into space, or the driver’s seat of a racing car at the Grand Prix.  

This insight has been carried through into a dedicated program for children. It includes an augmented-reality education platform that lets a child explore the upright treatment room on a phone or tablet before their first visit, guided by Leo the Lion, who also appears as a soft toy from the first oncology appointment and in Toby’s Magic Chair, a storybook following a young boy through upright treatment. 

Leo Cancer Care has also licensed a Stanford Medicine system called AVATAR: a radiolucent screen positioned in the child’s line of sight in the treatment room, designed to offer immersive distraction during treatment and reduce the need for anesthesia.

New research efforts and clinician guidance

A new report, Upright positioning in pediatric radiotherapy: rationale, safety considerations and a research roadmap, has been published in Technical Innovations & Patient Support in Radiation Oncology. It is the work of the Upright Radiotherapy Pediatric Task Group, an international, multiprofessional group spanning radiation oncology, medical physics, radiation therapy, pediatric anesthesia and industry, including Leo Cancer Care.

The report finds that upright positioning may reduce distress for selected children, while noting that pediatric-specific evidence remains limited. It outlines a research roadmap for upright radiotherapy in pediatric oncology and highlights the importance of standardized, safety-led workflows for children.

Challenging the conventions to deliver a more human way

Pediatric patients are the leading clinical application for proton therapy, and the children with the clearest indication have historically had the least access to it.

Leo Cancer Care’s aim is to make radiation therapy fit the patient rather than the other way around. Their upright platform opens access to the children who need protons most, and changes what the room asks of them once they are in it. It is a true nod to their vision of delivering radiation therapy in a more human way.

At the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting in Boston, Leo Cancer Care is sharing its clinical progress and vision for the future at booth 519.  

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/leo-cancer-care-unveils-bold-plans-to-improve-how-children-experience-radiotherapy-following-world-first-treatments-302890856.html

The standalone plugin lets any site deliver, protect, and track content created in tools like Articulate Storyline and Adobe Captivate, with every result added to a built-in learning record store. Full Uncanny Automator integration turns those results into completions, enrollments and other actions in LifterLMS, Tutor LMS, MemberPress Courses and other LMS plugins.

TORONTO, Sept. 27, 2026 /PRNewswire-PRWeb/ — Uncanny Owl, the Toronto-based WordPress company whose plugins are used by more than 80,000 organizations, today announced the launch of Tin Canny xAPI/SCORM for WordPress, a standalone plugin that lets any WordPress site deliver and track professionally authored eLearning content.

Course creators, agencies, and training teams build rich learning content in tools like Articulate Storyline and Rise, Adobe Captivate, iSpring, and Lectora, then export it as SCORM or xAPI packages. Until now, WordPress sites running an LMS other than LearnDash (or no LMS at all) have had limited options for hosting that content with real tracking: typically a hosted SCORM service that keeps learner data on its own platform and bills per user, or an external learning record store subscription alongside a separate player.

Tin Canny xAPI/SCORM for WordPress handles delivery and tracking in one plugin, on the customer’s own site. Uploaded modules play on any WordPress page or post, learners resume where they left off, and every completion, score, and xAPI statement is recorded in the site’s own database by a built-in learning record store — no external LRS required. Activity in SCORM 1.2 and SCORM 2004 packages are recorded as standards-compliant xAPI statements and appear as native xAPI records in the plugin’s filterable, CSV-exportable reports.

“Thousands of LearnDash sites have used Tin Canny to deliver and track their Storyline and Captivate courses for years,” said Ken Young, President of Uncanny Owl. “Users on other WordPress LMS plugins wanted similar functionality but were stuck with limited choices, which usually meant more complexity, more cost, or both. We’re excited to bring the simple, streamlined Tin Canny experience to those users.”

Through Uncanny Automator, module results integrate with the LMS a site already runs. When a module reports an xAPI verb such as “passed” or “completed,” or a score, Automator can mark a lesson, topic, quiz, or course complete, enroll the learner in a course, add them to a group, and more. For example, a low score can route a learner into a remedial course; a strong pre-assessment result can mark introductory lessons complete. Uncanny Automator already supports LifterLMS, Tutor LMS, MemberPress Courses, LearnPress, MasterStudy, and more. The actions available for each LMS are published on Automator’s per-platform integration pages.

“For a lot of organizations, the real requirement isn’t delivering the course, it’s proving it was completed,” said Young. “Knowing that a video played isn’t enough. They want a completion record with a timestamp and a score. That’s what Tin Canny produces, and the data lives in the organization’s own WordPress database, not on a platform they’re renting.”

Uploaded content is protected by server-level rules for Apache and NGINX plus per-request access control, and works alongside the membership and access-control plugins a site already uses. The plugin also tracks H5P content.

For LearnDash users, Tin Canny Reporting for LearnDash continues unchanged. Tin Canny xAPI/SCORM for WordPress is for sites running other WordPress LMS plugins, or for users that don’t want an LMS at all and simply want to be able to upload, deliver and track xAPI or SCORM activity without the complexity of an external LRS.

Availability

Tin Canny xAPI/SCORM for WordPress is available today, September 2, 2026, as a standalone plugin. Annual licenses start at $199 for a single site for the first year, with 5-site and 50-site licenses available. More information is at uncannyowl.com.

About Uncanny Owl

Uncanny Owl is a Toronto-based WordPress company. Its eLearning plugin suite — including Uncanny Toolkit, Uncanny Groups, Tin Canny Reporting for LearnDash, Uncanny Redemption Codes, and Uncanny Continuing Education Credits — is used by more than 30,000 organizations to run courses and training on WordPress. Uncanny Owl also makes Uncanny Automator, a WordPress AI and automation plugin. Learn more at uncannyowl.com and automatorplugin.com.

Media Contact

Aniefiok Ntia, Uncanny Owl, 234 08170046102, ani@uncannyowl.com

View original content to download multimedia:https://www.prweb.com/releases/uncanny-owl-launches-tin-canny-xapiscorm-for-wordpress-bringing-scorm-and-xapi-courses-to-any-wordpress-site-302888954.html

SOURCE Uncanny Owl

MADISON, Wis., Sept. 27, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. (“Samsung NeuroLogica”) to pursue advanced volumetric imaging capabilities for the CyberKnife® System. The announcement coincides with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray’s strategy to address customer priorities through targeted partnerships that bring together complementary expertise.

Accuray customers have consistently identified imaging capabilities that enhance treatment efficiency and informed decision-making as important priorities. Through this collaboration, Samsung NeuroLogica’s experience in mobile computed tomography (CT) and volumetric imaging will be coupled with Accuray’s expertise in precision treatment delivery, robotic radiosurgery, and motion management.

“When I joined Accuray, I spoke about the importance of bringing meaningful innovation to customers with greater focus and speed,” said Steve La Neve, President and Chief Executive Officer of Accuray. “That requires clarity about where Accuray should lead, where we should collaborate, and how we translate customer priorities into action. Our collaboration with Samsung NeuroLogica reflects that approach by bringing together complementary expertise to pursue opportunities that are expected to help address important customer and patient needs.”

Leading practitioners have emphasized to Accuray that volumetric imaging can enhance visualization of patient anatomy in the treatment environment and support future clinical workflows. The collaboration between Accuray and Samsung NeuroLogica is intended to pursue opportunities to bring additional imaging information closer to treatment decision-making while maintaining the regulatory rigor required in radiation oncology.

“We have long been interested in what volumetric imaging could add to CyberKnife’s non-coplanar treatment delivery and real-time motion management,” said Professor Nicholas van As, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust and Chief Investigator of the landmark PACE trials, which have helped establish five-fraction radiotherapy as a standard of care for selected patients with localised prostate cancer. “Seeing the target and surrounding anatomy together at the time of treatment could help us make more informed decisions for each patient. Looking further ahead, this could open new possibilities for adapting treatment to the patient’s anatomy of the day, alongside real-time motion management during delivery. We are delighted that The Royal Marsden is the first centre worldwide to participate in this Accuray–Samsung NeuroLogica collaboration, exploring what Samsung’s volumetric imaging technology could bring to the future of robotic radiosurgery.”

“The potential of volumetric imaging alongside robotic radiosurgery extends across thoracic, abdominal and pelvic malignancies,” said Jonathan Lischalk, MD, Clinical Director of Radiosurgery at MedStar Georgetown University Hospital and Clinical Associate Professor at Georgetown University School of Medicine, who will speak at Accuray’s clinical session at ASTRO on Monday, September 28. “For clinicians treating lung, pancreatic and prostate cancers, understanding the relationship between the target and nearby healthy organs at the time of treatment is central to the decisions we make. Exploring how additional imaging information could complement CyberKnife’s non-coplanar delivery and real-time motion management is an exciting direction. Looking further ahead, it could also open new possibilities for adapting treatment to changing anatomy. I look forward to discussing these clinical opportunities with colleagues at ASTRO.”

The feedback from leading clinicians reinforces the importance of pursuing innovations that can provide additional information at the time of treatment.

“Our team has spent years developing mobile CT, bringing imaging to the patient. The discussion with Accuray begins with a practical clinical need: better visualization of anatomy in the treatment room,” said Boris Geyzer, Head of Business, Mobile CT, Samsung HME America. “Samsung NeuroLogica brings deep experience in mobile computed tomography, while Accuray brings precision treatment-delivery expertise and a close understanding of radiotherapy workflows. By bringing these perspectives together, we believe that we can facilitate use of volumetric imaging to address meaningful needs in the treatment room.”

The Samsung NeuroLogica collaboration is one component of Accuray’s broader strategy to accelerate innovation and product development through a deliberate combination of internally developed technologies and strategic partnerships.

“Customers expect us to move with urgency while maintaining the discipline required in radiation therapy,” La Neve added. “We do not believe every capability must be developed internally. In many cases, the strongest path forward is bringing together distinct expertise around a shared customer or patient challenge.”

The collaboration will progress through phased development activities as the companies evaluate technical, clinical, and commercial opportunities. No commercial product offering has been announced, and future developments remain subject to ongoing evaluation and applicable regulatory requirements.

The announcement reinforces Accuray’s commitment to helping clinicians deliver highly precise treatments while advancing the company’s mission to expand the curative power of radiation therapy and improve as many lives as possible.

About Accuray

Accuray is committed to expanding the potential of radiation therapy to improve as many lives as possible. The company develops unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases easier, helping to meet the full spectrum of patient needs. Accuray is dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery and beyond. Through collaboration with clinicians and administrators, the company aims to empower healthcare professionals to help patients return to their lives faster. Accuray is headquartered in Madison, Wisconsin, USA, and has facilities worldwide. For more information, please visit http://www.accuray.com 

About Samsung Healthcare USA

Samsung Healthcare USA is the unified brand for Samsung HME (Healthcare and Medical Equipment) America, bringing advanced medical imaging solutions to healthcare providers across the United States, including Ultrasound, Digital Radiography, and Computed Tomography. Samsung HME America also serves as the global manufacturing center for Samsung’s mobile Computed Tomography business, leading the development and production of advanced CT systems used by healthcare providers worldwide. As part of the Samsung Healthcare family, Samsung HME America drives the sales, marketing, service, and support of Samsung Healthcare’s imaging solutions across the United States. For more information, please visit: https://usa.samsunghealthcare.com/.

Forward-Looking Statements

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding collaborations and strategic partnerships with third parties, including the collaboration with Samsung NeuroLogica, and the company’s ability to address customer priorities and bring meaningful innovation to customers. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the ability of the company to execute upon its transformation plan; the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; the company’s ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the company’s ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company’s ability to maintain or increase its gross margins on product sales and services; the company’s ability to convert backlog to revenue; and such other risks identified under the heading “Risk Factors” in the company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on August 27, 2026, and as updated periodically with the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Accuray Media Contact
Taylor Bould
Communications Specialist, Accuray
+1 (608) 830-3604
tbould@accuray.com

Samsung Healthcare USA Media Contact
Anthony Tardi
Samsung HME America
978.564.8500
atardi@samsunghme.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-and-samsung-neurologica-advance-volumetric-imaging-collaboration-for-the-accuray-cyberknife-platform-302890828.html

SOURCE Accuray Incorporated